Previous Close | 3.1300 |
Open | 3.2900 |
Bid | 3.1600 x 21500 |
Ask | 3.1500 x 2900 |
Day's Range | 2.9500 - 3.3000 |
52 Week Range | 2.0900 - 15.8640 |
Volume | |
Avg. Volume | 23,095,638 |
Market Cap | 5.579B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.6720 |
Earnings Date | Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.41 |
Today we will run through one way of estimating the intrinsic value of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) by...
A look at the shareholders of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) can tell us which group is most powerful...
TORONTO and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo’s platform for organism design and development, Cronos has successfully achieved the productivity ta